Full Press Release Details
Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
Fla., April 29, 2026 - INVO Fertility, Inc. (Nasdaq: IVF) ("INVO" or the "Company"), a healthcare
services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and
operation of fertility clinics and related businesses and technologies, today announced that on April 23, 2026, it received a written
notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying
the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies
to timely file all required periodic financial reports with the Securities and Exchange Commission ("SEC"). Specifically,
the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "Annual Report"),
which was due no later than April 15, 2026.
Notice has no immediate effect on the listing of the Company's common stock on Nasdaq, and the Company's common stock will
continue to trade on Nasdaq under the symbol "IVF" at this time.
Company is working diligently to complete and file the Annual Report as soon as practicable. The delay in filing is due to additional
time required to review certain complex accounting matters, including the tax provision accounting, certain warrant accounting, and variable interest entity accounting . The Company intends to file the Annual Report as promptly as possible.
to Nasdaq Listing Rule 5810(c)(2)(F), the Company has 60 calendar days from the date of the Notice to submit a plan to Nasdaq to regain
compliance with the Rule. If Nasdaq accepts the Company's plan, Nasdaq may grant the Company up to 180 calendar days from the due
date of the Annual Report to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the opportunity
to appeal that decision before a Nasdaq Hearings Panel.
press release is being issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt public disclosure of receipt of a deficiency
are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology ("ART") care
to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including
"INVO Centers" dedicated primarily to offering the intravaginal culture ("IVC") procedure enabled by our INVOcell
medical device ("INVOcell") and US-based, profitable in vitro fertilization ("IVF") clinics. We have four operational
fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and
operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early
embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected,
intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results
at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more
information, please visit invofertility.com.
release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform
Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business
strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations,
as well as statements that include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies,
many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated
results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements
include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation
to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
more information, please contact: